Neoantigen specific TCR-T cell therapy

N/A

Report date: 2025/11/11 20:00:28

Base Information

Drug NameNeoantigen specific TCR-T cell therapy
Drug Alias NameNeoantigen specific TCR-T cell drug product
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Gene therapy > Gene editing > Sleeping Beauty transposon/transposase systemCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocytes modulators
TargetsNot applicable
Therapy Area/IndicationsEndometrial NeoplasmsGenital Neoplasms, FemaleCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlaunos Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlaunos Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsEndometrial NeoplasmsGenital Neoplasms, FemaleCarcinoma, Non-Small-Cell Lung +[10] 

Other Information

ATC CodeN/A
Related LinksN/A